Aeterna Zentaris Inc. (NASDAQ:AEZS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

AEZS has been the subject of a number of other research reports. Canaccord Genuity restated a “buy” rating and set a $9.00 target price on shares of Aeterna Zentaris in a report on Tuesday, August 23rd. Maxim Group restated a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a report on Wednesday, June 15th. Finally, HC Wainwright restated a “buy” rating on shares of Aeterna Zentaris in a report on Thursday, August 11th.

Aeterna Zentaris (NASDAQ:AEZS) traded up 3.29% during midday trading on Tuesday, hitting $3.45. The stock had a trading volume of 161,660 shares. Aeterna Zentaris has a 52 week low of $2.60 and a 52 week high of $15.70. The firm has a 50 day moving average of $3.51 and a 200 day moving average of $3.54. The firm’s market cap is $34.29 million.

Aeterna Zentaris (NASDAQ:AEZS) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.11. Aeterna Zentaris had a negative return on equity of 241.78% and a negative net margin of 5,871.45%. Equities research analysts predict that Aeterna Zentaris will post ($2.61) EPS for the current year.

A hedge fund recently raised its stake in Aeterna Zentaris stock. Renaissance Technologies LLC raised its stake in shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned 8.17% of Aeterna Zentaris worth $1,716,000 at the end of the most recent reporting period. 8.28% of the stock is owned by institutional investors and hedge funds.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.